The cost of Alzheimer's disease in China and re-estimation of costs worldwide

  title={The cost of Alzheimer's disease in China and re-estimation of costs worldwide},
  author={Jianping Jia and Cuibai Wei and Shuoqi Chen and Fangyu Li and Yi Tang and Wei Qin and Lina Zhao and Hongmei Jin and Hui Xu and Fen Wang and Ai-hong Zhou and Xiu-mei Zuo and Liyong Wu and Ying Han and Yue Han and Liyuan Huang and Qi Wang and Dan Li and Changbiao Chu and Lu Shi and Min Gong and Yifeng Du and Jiewen Zhang and Junjian Zhang and Chunkui Zhou and Jihui Lv and Yang Lv and Haiqun Xie and Yong Ji and Fang Li and Enyan Yu and Ben-yan Luo and Yanjiang Wang and Shanshan Yang and Qiumin Qu and Qihao Guo and Furu Liang and Jintao Zhang and Lan Tan and Lu Shen and Kunnan Zhang and Jinbiao Zhang and Dantao Peng and Muni Tang and Peiyuan Lv and Boyan Fang and Lan Chu and Longfei Jia and Serge Gauthier},
  journal={Alzheimer's \& Dementia},

Association between atherosclerosis and Alzheimer's disease: A systematic review and meta‐analysis

A systematic review and meta‐analysis was conducted to study the difference of carotid intima–media thickness (CIMT) and the prevalence of atherosclerosis between AD patients and non‐AD controls.

Metformin and the risk of neurodegenerative diseases in patients with diabetes: A meta‐analysis of population‐based cohort studies

The association between metformin use and neurodegenerative disease (ND) onset remains controversial and a systematic review and meta‐analysis based on data from population‐based cohort studies aimed to determine the relationship.

Recent advances in research on Alzheimer's disease in China

Cost Effectiveness Analysis of Alzheimer's Disease

Early and moderate-stage treatment of AD is cost-effective compared to severestage treatment, and the social and economic costs increased and the quality of life of the patients decreased in the progress stages of AD.

Associated Factors of Total Costs of Alzheimer's Disease: A Cluster-Randomized Observational Study in China.

In China, AD severity and comorbidities were the most critical factors impacting the total cost, and Optimizing care patterns, delaying disease progression, and managing comorebidities comprehensively could decrease the heavy burden of AD.

The efficacy of statins in the treatment of Alzheimer’s disease: a meta-analysis of randomized controlled trial

Investigation of the effect of statins in the treatment of Alzheimer’s disease found that statins could slow the deterioration of neuropsychiatric status and significantly improve activities of daily living ability in AD patients, but statins did not show an advantage in the change of the ADAS-Cog scale scores.

The Economic Burden of Alzheimer's Disease in Zhejiang Province.

The economic burden of AD in Zhejiang Province is heavy, similar to the national burden, and interventions based on demographic characteristics and disease severity can help reduce it.

Major Cost Drivers in Assessing the Economic Burden of Alzheimer’s Disease: A Structured, Rapid Review

The contribution of healthcare costs to the overall burden of Alzheimer’s Disease was not negligible; but was generally exceeded by social and informal care costs.

The impacts of health insurance and resource on the burden of Alzheimer's disease and related dementias in the world population.

  • Jin-Tao WangGang Xu G. Wang
  • Medicine, Political Science
    Alzheimer's & dementia : the journal of the Alzheimer's Association
  • 2022
The collected global data showed an increased burden of ADRD on patients both physically and economically, and health resources were negatively associated with disability-adjusted life years, death, and years of life lost, but were otherwise positively associated with years of lived with disability.

The China Alzheimer Report 2022

The public health impact of ADRD, including prevalence, mortality, costs, usage of care, and the overall effect on caregivers and society is examined, as well as an information platform for international exchange and cooperation is suggested.



The worldwide costs of dementia 2015 and comparisons with 2010

The worldwide economic impact of dementia 2010

The economic impact of dementia in Europe in 2008—cost estimates from the Eurocode project

Care for demented people is very resource demanding, the prevalence is increasing and there is so far no cure.

Predictors of costs of care in Alzheimer’s disease: A multinational sample of 1222 patients

The prevalence of dementia in urban and rural areas of China

Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China.

Assessment of the economic cost of Alzheimer's disease in Shanghai, China found total cost was significantly associated with the degree of severity including cognitive function (MMSE) and activity of daily living (ADL).

Cross sectional observational study on the societal costs of Alzheimer's disease.

The societal costs of AD are very high, especially for patients with moderate and severe AD, which implies that treatments with the ability to delay progression of the disease into more severe stages have the potential to save large costs for society.

Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina

With the projected increase in the number of persons at risk for developing AD in emerging countries, the family cost of the disease will be significant and should be a matter of analysis when health policies are being designed in developing countries.

Monetary costs of Alzheimer’s disease in China: protocol for a cluster-randomised observational study

This is the first large-scale cluster-randomized observational study to estimate the economic burden of AD in Chinese patients and the methodology used was based on China’s current healthcare system and is suitable for the purpose of the study.